Cargando…

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

AIMS: Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tardif, Jean-Claude, Karwatowska-Prokopczuk, Ewa, Amour, Eric St, Ballantyne, Christie M, Shapiro, Michael D, Moriarty, Patrick M, Baum, Seth J, Hurh, Eunju, Bartlett, Victoria J, Kingsbury, Joyce, Figueroa, Amparo L, Alexander, Veronica J, Tami, Joseph, Witztum, Joseph L, Geary, Richard S, O’Dea, Louis St L, Tsimikas, Sotirios, Gaudet, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986458/ https://www.ncbi.nlm.nih.gov/pubmed/35025993 http://dx.doi.org/10.1093/eurheartj/ehab820

Ejemplares similares

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
por: Gaudet, Daniel, et al.
Publicado: (2020)

Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers
por: Watts, Lynnetta M., et al.
Publicado: (2020)

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
por: Alexander, Veronica J, et al.
Publicado: (2019)

FRI092 Rationale And Design Of The Balance Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Olezarsen In Patients With Familial Chylomicronemia Syndrome
por: Alexander, Veronica, et al.
Publicado: (2023)

Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study
por: Foss-Freitas, Maria C., et al.
Publicado: (2021)

Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements
por: Yeang, Calvin, et al.
Publicado: (2021)

Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles
por: O’Dea, Louis St L, et al.
Publicado: (2019)

Severe hypertriglyceridaemia during treatment with capecitabine
por: Javot, L, et al.
Publicado: (2011)

Acute Pancreatitis Secondary to Gestational Hypertriglyceridaemia
por: Cahalane, Alexis M., et al.
Publicado: (2012)

An unusual case of (pseudo)hypertriglyceridaemia
por: Speeckaert, Marijn M., et al.
Publicado: (2010)

Propofol: Hypertriglyceridaemia: case report
Publicado: (2022)

Development and validation of an isoform-independent monoclonal antibody–based ELISA for measurement of lipoprotein(a)
por: Marcovina, Santica M., et al.
Publicado: (2022)

Role of the Enterocyte in Fructose-Induced Hypertriglyceridaemia
por: Steenson, Simon, et al.
Publicado: (2017)

Severe Hypertriglyceridaemia Leading to Factitious Hypobicarbonataemia
por: Roy, Sasmit, et al.
Publicado: (2021)

Hypertriglyceridaemia associated with propofol sedation in critically ill patients
por: Mateu, J., et al.
Publicado: (1996)

Catecholamines/propofol/vasopressin: Hypertriglyceridaemia: case report
Publicado: (2020)

Hypertriglyceridaemia in pregnancy: an unexpected diagnosis and its management
por: Barclay, Kathryn, et al.
Publicado: (2022)

Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
por: Parhofer, Klaus G, et al.
Publicado: (2020)

Comprehensive review on the pathogenesis of hypertriglyceridaemia-associated acute pancreatitis
por: Qiu, Minhao, et al.
Publicado: (2023)

Antisense Inhibition of Angiotensinogen With IONIS-AGT-L(Rx): Results of Phase 1 and Phase 2 Studies
por: Morgan, Erin S., et al.
Publicado: (2021)

Atypical presentation of a middle age male with severe hypertriglyceridaemia: a case report
por: Albahrani, Ali I, et al.
Publicado: (2007)

High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction
por: Taleb, Adam, et al.
Publicado: (2023)

Oxidation-specific epitopes restrain bone formation
por: Ambrogini, Elena, et al.
Publicado: (2018)

Hypertriglyceridaemia in extremely preterm infants receiving parenteral lipid emulsions
por: Sinclair, Ruth, et al.
Publicado: (2018)

Propofol: Hypertriglyceridaemia secondary to propofol infusion syndrome: case report.
Publicado: (2021)

Tocilizumab: Acute hypertriglyceridaemia and off-label use: case report
Publicado: (2020)

Hypertriglyceridaemia: contemporary management of a neglected cardiovascular risk factor
por: Khan, Tina Z., et al.
Publicado: (2021)

Hypertriglyceridaemia-Induced Acute Pancreatitis: A Different Disease Phenotype
por: Dancu, Greta, et al.
Publicado: (2022)

Covid-19-vaccine-pfizer-biontech: Hypertriglyceridaemia: case report
Publicado: (2022)

Efficacy of insulin in treating severe hypertriglyceridaemia in the third trimester of pregnancy
por: Zhou, Dong, et al.
Publicado: (2022)

Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease
por: Amir, Shahzada, et al.
Publicado: (2012)

A Neutralizing Antibody Targeting Oxidized Phospholipids Promotes Bone Anabolism in Chow‐Fed Young Adult Mice
por: Palmieri, Michela, et al.
Publicado: (2020)

Unmasking of severe hypertriglyceridaemia associated with antipsychotic therapy by atypical eruptive xanthomas
por: Kiedrowicz, Magdalena, et al.
Publicado: (2017)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
por: Greffrath, Wilhelm P., et al.
Publicado: (2018)

Hypertriglyceridaemia delays pancreatic regeneration after acute pancreatitis in mice and patients
por: Yang, Na, et al.
Publicado: (2019)

Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19
por: Nakamura, Hideta, et al.
Publicado: (2020)

A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
por: Ward, Natalie C., et al.
Publicado: (2022)

Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome—Causes, Clinical Presentation, and Therapeutic Options
por: Bashir, Bilal, et al.
Publicado: (2023)

The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study
por: Michie, C O, et al.
Publicado: (2010)

IGHV1-69-Encoded Antibodies Expressed in Chronic Lymphocytic Leukemia React with Malondialdehyde–Acetaldehyde Adduct, an Immunodominant Oxidation-Specific Epitope
por: Que, Xuchu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8kavq40rreo75sqdefprr9726e